Rocket Pharmaceuticals, Inc. (RCKT): R&D Expense
$142.01M
Year ended 2025-12-31
$124.37M
Trailing 12 months to 2026-06-30
-5.0%
3-year compound annual growth
+6.1%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $142.01M | -17.1% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $171.24M | -8.1% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $186.34M | +12.5% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $165.57M | +32.0% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $125.48M | +19.0% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $105.44M | +82.1% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $57.91M | n/c | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $53.27M | +257.1% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $14.92M | +148.9% | 2019-03-08, From 2017-01-01 |
| 2016-12-31 | $5.99M | -52.3% | 2019-03-08, From 2016-01-01 |
| 2015-12-31 | $12.55M | +124.5% | 2017-03-16, From 2015-01-01 |
| 2014-12-31 | $5.59M | n/a | 2016-03-23, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $142.01M | -17.1% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare RCKT, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗